Journal of Hepatology
Volume 54, Issue 1 , Pages 89-97 , January 2011

Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria

  • Wolfgang Sieghart

      Affiliations

    • Abteilung Gastroenterologie and Hepatologie, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Xiaowei Wang

      Affiliations

    • Abteilung Gastroenterologie and Hepatologie, Medizinische Universität and AKH Wien, Vienna, Austria
    • Dept. of Internal Medicine, China Japan Union Hospital, Jilin University, China
    • ,
  • Katharina Schmid

      Affiliations

    • Klinik für Pathologie, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Matthias Pinter

      Affiliations

    • Abteilung Gastroenterologie and Hepatologie, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Franz König

      Affiliations

    • Institut für Medizinische Statistik, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Martin Bodingbauer

      Affiliations

    • Abteilung Transplantchirurgie, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Fritz Wrba

      Affiliations

    • Klinik für Pathologie, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Susanne Rasoul-Rockenschaub

      Affiliations

    • Abteilung Transplantchirurgie, Medizinische Universität and AKH Wien, Vienna, Austria
    • ,
  • Markus Peck-Radosavljevic

      Affiliations

    • Abteilung Gastroenterologie and Hepatologie, Medizinische Universität and AKH Wien, Vienna, Austria
    • Corresponding Author InformationCorresponding author. Address: Abteilung Gastroenterologie and Hepatologie, Medizinische Universität and AKH Wien, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Tel.: +43 1 40400 6589; fax: +43 1 40400 4735.

Received 3 December 2009 ,Revised 16 June 2010 ,Accepted 18 June 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  3. Primary Liver Cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990;211:277–287.
  4. Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990;211:28–33
  5. Genda T, Sakamoto M, Ichida T, Asakura H, Kojiro M, Narumiya S, et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology. 1999;30:1027–1036
  6. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer. 1990;66:2174–2179
  7. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991;110:726–734[discussion 734–725]
  8. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology. 1994;20:33S–40S
  9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [see comments]. N Engl J Med. 1996;334:693–699
  10. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transplant. 2004;10:911–918
  11. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652–659
  12. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228:479–490
  13. Vauthey JN, Klimstra D, Franceschi D, Tao Y, Fortner J, Blumgart L, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995;169:28–34discussion 34-25
  14. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55–76
  15. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–127
  16. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416–423
  17. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:2051–2059
  18. Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709–717
  19. Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn’s disease. Scand J Immunol. 2007;65:453–460
  20. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723–749
  21. Furger KA, Menon RK, Tuckl AB, Bramwelll VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001;1:621–632
  22. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 2002;52:19–24
  23. Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983;302:714–715
  24. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene. 1996;13:97–104
  25. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res. 2004;121:228–241
  26. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782–789
  27. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 2007;121:1717–1723
  28. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1087–1097
  29. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007;133:643–652
  30. Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer. 2007;57:302–310
  31. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68:152–161
  32. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev. 2008;8:212–226
  33. International Union Against Cancer (UICC). Liver. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours, 6th ed. New York, NY: Wiley & Sons; 2002. p. 74–76.
  34. Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503
  35. Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P, Geszner R, et al. Tumor-Associated Angiogenesis and Lymphangiogenesis Correlate With Progression of Intrahepatic Cholangiocarcinoma. Am J Gastroenterol. 2010;105:1123–1132
  36. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994;145:610–623
  37. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Human Pathol. 2008;39:1777–1783
  38. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700–5706
  39. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transplant. 2002;8:765–774
  40. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43
  41. Iizuka N, Hamamoto Y, Oka M. Predicting individual outcomes in hepatocellular carcinoma. Lancet. 2004;364:1837–1839
  42. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513–521
  43. Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008;135:956–968
  44. Sun B-S, Dong Q-Z, Ye Q-H, Sun H-J, Jia H-L, Zhu X-Q, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008;48:1834–1842
  45. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361–6371

PII: S0168-8278(10)00722-1

doi: 10.1016/j.jhep.2010.06.030

Journal of Hepatology
Volume 54, Issue 1 , Pages 89-97 , January 2011

Article Tools

* Image Usage & Resolution